Clinical trialsCompany release
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026
The Canadian company has asked Health Canada to amend its OPTI-101 protocol and expects to start an MDMA-assisted therapy Phase 3 in PTSD in 2027.
Optimi Health Corp. said on 18 November 2026 that it has asked Health Canada to approve a protocol amendment to its open-label psilocybin study, OPTI-101, in severe major depressive disorder. The change would convert the study into a randomised, double-blind Phase 2b trial in 200 adults.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Optimi Health Corp. ↗
Article written by VigiEye from the official source (Optimi Health Corp.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
Can-Fite BioPharma Ltd. (CANF) · Wed 18 Nov 2026